Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis.
van Nimwegen-Campailla
L
L
van Beveren
N
N
Laan
W
W
van den Brink
W
W
Linszen
D
D
de Haan
L
L
D000342:Affective Symptoms / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008385:Marijuana Smoking; D055118:Medication Adherence; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine